Select Media

Redwood City, Calif. – November 18, 2016 – The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued a substantial revision to its COPD management recommendations that now includes bronchoscopic lung volume reduction with endobronchial valves as a treatment option for patients with advanced emphysema and absence of collateral ventilation. The updated recommendations are based Read More

Redwood City, Calif. – October 5, 2016 – Pulmonx, a leader in interventional pulmonology, today announced completion of enrollment in its pivotal IDE study – the LIBERATE Trial – a randomized, controlled, multi-center study of the Zephyr® Endobronchial Valve (EBV) in patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Results from Read More

Results Published in American Journal of Respiratory and Critical Care Medicine Show Meaningful Improvements in Patient Lung Function, Exercise Tolerance and Quality of LifeRedwood City, Calif. – Sept 5, 2016 – Positive results from the IMPACT study demonstrate that patients with homogeneous emphysema benefit from treatment with Pulmonx Corporation’s proprietary Zephyr® Endobronchial Valves (EBV), according Read More